PeptiDream licenses PDPS technology to Genentech

Under the terms of the agreement, PeptiDream will receive an undisclosed upfront payment, annual technology access payments, and is eligible to receive payments based on achievement of certain predetermined development milestones.

In addition, PeptiDream is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology.

PeptiDream will continue to work with Genentech to identify macrocyclic/constrained peptides against multiple targets of interest selected by Genentech, and to optimize hit peptides into therapeutic peptides or small molecule products using PeptiDream’s PDPS technology, under the original agreement in December 2015.

In the past six years, PeptiDream has established funded discovery collaborations with 15 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, and Asahi Kasei, all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, and Lilly.

Kiichi Kubota, President & CEO of PeptiDream, said: “Genentech is now the 4th company to internalize our PDPS technology, joining Bristol-Myers Squibb, Novartis, and Lilly. Our PDPS technology aims to target sites not identified by conventional methods, which can then serve as the starting point for the discovery and development of either peptide or small molecule based therapeutics.

"The license with Genentech is a further testament to the power of our PDPS technology and how it is changing the way drugs are discovered.”